AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Diffuse Large B Cell Lymphoma Refractory

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies NCT07284433Phase 1, Phase 213 sites๐Ÿ“ Chicago๐Ÿ“ Evanston๐Ÿ“ Providence AvenCell Therapeutics, Inc. ยท Tests: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946Phase 16 sites๐Ÿ“ Duarte๐Ÿ“ St Louis๐Ÿ“ Buffalo LTZ Therapeutics, Inc. ยท Tests: LTZ-301, LTZ-301, LTZ-301 A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites๐Ÿ“ Santander๐Ÿ“ Salamanca๐Ÿ“ Barcelona IDP Discovery Pharma S.L. ยท Tests: IDP-121 A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma NCT07044050Phase 11 site๐Ÿ“ Montpellier Emercell SAS ยท Tests: allogenic natural killer cells Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690Phase 12 sites๐Ÿ“ Houston๐Ÿ“ Houston Baylor College of Medicine ยท Tests: C7R.CD30.CAR-EBVST cells Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma NCT07763210Phase 21 site๐Ÿ“ Nashville Vanderbilt-Ingram Cancer Center ยท Tests: Therapeutic Hydrocortisone, Cytarabine, Dexamethasone, Methylprednisolone, Cyclophosphamide Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT03936153Phase 223 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Beijing Xynomic Pharmaceuticals, Inc. ยท Tests: abexinostat SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites๐Ÿ“ Denver๐Ÿ“ Atlanta๐Ÿ“ Fairway Verismo Therapeutics ยท Tests: SynKIR-310 Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06015880Phase 18 sites๐Ÿ“ Duarte๐Ÿ“ Sacramento๐Ÿ“ Tampa National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Computed Tomography, Lenalidomide, Mosunetuzumab, Polatuzumab Vedotin Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL NCT05552937Phase 21 site๐Ÿ“ Hangzhou Beijing InnoCare Pharma Tech Co., Ltd. ยท Tests: Tafasitamab and Lenalidomide A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL NCT05514327NA1 site๐Ÿ“ Beijing Peking Union Medical College Hospital ยท Tests: ultra-fraction radiotherapy Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies NCT05887167Phase 11 site๐Ÿ“ Los Angeles Joshua Sasine, MD, PhD ยท Tests: autologous hematopoietic stem cells added to planned CAR T GVMยฑR in Patients With Relapsed or Refractory Aggressive NHL. NCT06244368Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: GVMยฑR regimen Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527Phase 17 sites๐Ÿ“ Duarte๐Ÿ“ Chicago๐Ÿ“ New York AIDS Malignancy Consortium ยท Tests: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma NCT06854445Phase 224 sites๐Ÿ“ Wuhu๐Ÿ“ Xiamen๐Ÿ“ Lanzhou Shanghai Chia Tai Tianqing Pharmaceutical Technology Develoโ€ฆ ยท Tests: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726Phase 21 site๐Ÿ“ Seattle University of Washington ยท Tests: Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therโ€ฆ Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) NCT06299553n/a1 site๐Ÿ“ Milan Incyte Biosciences Italy S.r.l Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT07197307Phase 234 sites๐Ÿ“ Aachen๐Ÿ“ Augsburg๐Ÿ“ Berlin Universitรคt Mรผnster ยท Tests: Loncastuximab Tesirine and Epcoritamab CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319Phase 11 site๐Ÿ“ Boston Marcela V. Maus, M.D.,Ph.D. ยท Tests: CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies NCT06528301Phase 19 sites๐Ÿ“ Duarte๐Ÿ“ Chicago๐Ÿ“ Grand Rapids Umoja Biopharma ยท Tests: UB-VV111, rapamycin Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma NCT03223610Phase 1, Phase 21 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Revlimid (lenalidomide) Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049Phase 1, Phase 23 sites๐Ÿ“ Minneapolis๐Ÿ“ Columbus๐Ÿ“ Richmond Yazeed Sawalha ยท Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies NCT06227026Phase 11 site๐Ÿ“ Salt Lake City University of Utah ยท Tests: Anti-CD19 CAR-T cells Low Dose Epcoritamab Plus GemOx in R/R DLBCL NCT07451652Phase 21 site๐Ÿ“ Monterrey Hospital Universitario Dr. Jose E. Gonzalez ยท Tests: Epcoritamab, Gemcitabine (1000 mg/m2), Oxaliplatin Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy NCT06834373Phase 27 sites๐Ÿ“ Scottsdale๐Ÿ“ Jacksonville๐Ÿ“ Albert Lea Mayo Clinic ยท Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed โ€ฆ Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders NCT06672705Phase 12 sites๐Ÿ“ St Louis๐Ÿ“ Columbus Timothy Voorhees ยท Tests: Biopsy, Biospecimen Collection, Computed Tomography, Epcoritamab, Positron Emission Tomography An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT06517004Phase 11 site๐Ÿ“ Shanghai Fudan University ยท Tests: JWCAR201 A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies NCT07735533Phase 1, Phase 21 site๐Ÿ“ Nashville Umoja Biopharma ยท Tests: UB-VV400, Rapamycin (sirolimus) Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL NCT06570447Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: Glofitamab, Chidamide A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites๐Ÿ“ Gilbert๐Ÿ“ Scottsdale๐Ÿ“ Scottsdale Lyell Immunopharma, Inc. ยท Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy